NCT05821452View on ClinicalTrials.gov

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 25, 2023

Primary Completion Date

May 25, 2024

Study Completion Date

May 30, 2026

Conditions
ChemotherapyRadiation Therapy
Interventions
DRUG

Camrelizumab

200mgQ3w

DRUG

Paclitaxel

175mg/m2，D1，Q3w

DRUG

Cisplatin

75mg/m2，D1，Q3w

RADIATION

Radiotherapy

41.4Gy, 1.8Gy each time, 5 times a week

Trial Locations (1)

350001

Fujian Medical University Union Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Medical University Union Hospital

OTHER

NCT05821452 - Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma | Biotech Hunter | Biotech Hunter